Previous 10 | Next 10 |
Audentes Therapeutics , Inc. (BOLD) Q12 2019 Results Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Andrew Chang – Head-Investor Relations Matt Patterson – Chairman and Chief Executive Officer Conference Call Participants Anupam Rama ȁ...
Audentes Therapeutics (NASDAQ: BOLD ): Q1 GAAP EPS of -$1.13 misses by $0.24 . Cash and equivalents of $378.8M. Press Release More news on: Audentes Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
SAN FRANCISCO , May 7, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the fi...
The following slide deck was published by Audentes Therapeutics, Inc. in conjunction with this Read more ...
Updated data from a Phase 1/2 clinical trial, ASPIRO , evaluating Audentes Therapeutics' ( BOLD -0.6% ) gene therapy candidate AT132 in patients with X-linked myotubular myopathy (XLMTM) showed a treatment effect. The results were presented at the American Society of Gene and Cell Ther...
SAN FRANCISCO , May 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced new positive data from ASPIRO, ...
SAN FRANCISCO , April 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to r...
SAN FRANCISCO , April 23, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced the launch of a new sta...
SAN FRANCISCO , April 15, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced multiple planned presen...
The following slide deck was published by Audentes Therapeutics, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Audentes Therapeutics Inc. Company Name:
BOLD Stock Symbol:
NASDAQ Market:
Audentes Therapeutics Inc. Website:
Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer,...
BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will...